



Innovative Medicines to Fight Non-Communicable Diseases


Solutions to Combat Non-Communicable Diseases Around the World

The pharmaceutical industry has long recognized the economic and social burden of Non-Communicable Diseases (NCDs) and has been working with governments, health care providers, patients groups and other stakeholders as an active solution partner in lessening this burden. The industry promotes and supports health prevention and promotion strategies and patient-centered approaches to managing chronic conditions and their risk factors. At the same time the global biopharmaceutical industry leads the search for new cures and the research and development of new medicines to treat or prevent non-communicable diseases. There are currently thousands of medicines either in clinical trials or awaiting approval to treat NCDs.

Countries with developed health care systems have shown that successful prevention programs coupled with the effective use of medicines have led to decreased mortality from chronic disease. The burden of disease attributed to NCDs worldwide is 85% in industrialized nations, 70% in middle-income and nearly 50% in low-income nations.ⁱ In fact, in 2005, chronic diseases accounted for 35 million of the 58 million deaths worldwide. This is twice the number of deaths attributed to all infectious diseases, maternal and perinatal conditions and nutritional deficiencies.ⁱⁱ There is an indirect correlation between burden of disease and deaths from NCDs based on a country's income level – 80% of chronic disease deaths occur in low and middle income countries, with only 20% occurring in higher income countries.ⁱⁱⁱ Figure 1 indicates geographic distribution of chronic disease deaths.

Figure 1

Projected Global Distribution of Chronic Disease Deaths *by World Bank income group, all ages, 2005*



SOURCE: World Health Organization; *Preventing Chronic Diseases a Vital Investment*; World Health Organization Cataloguing-in-Publication Data, 2005, pg. 8


2 Innovative Medicines to Fight Non-Communicable Diseases

In recent years, global biopharmaceutical companies have steadily increased their efforts to research and develop new medicines and interventions targeting diseases and unique barriers that are found primarily in the developing world. These research facilities, located around the world, are specifically focusing on finding new and better treatments and encouraging healthcare solutions. Notable special programs undertaken by pharmaceutical companies include:

- Supporting a Brazilian NGO to provide medical and educational aid to mothers with chronically ill children living below the poverty line. Mothers are taught how to create healthy environments and given the skills to do so.^{iv}
- Training Venezuelan doctors at the respiratory care centers in the Chacao neighborhood and the Pérez de León Hospital in Caracas. The hospital also receives free medicines and equipment.^v
- Providing cancer and tobacco control organizations in 46 countries with training and technical assistance, national cancer control plans and improvement of patient services. The program collaborates with local experts to improve the diagnosis and treatment of cancer and reduce its incidence and burden.^{vi}
- Undertaking a four-year, multimillion dollar collaborative program designed to help health care workers in India reduce morbidity and mortality related to diabetes and to combat the rapidly growing threat of diabetes in India through Project Hope.^{vii}
- Laying the foundations for Chronic Obstructive Pulmonary Disease (COPD) education in China in partnership with the Chinese Medical Association. To help raise awareness of COPD, the COPD Academic Award was established in 1995 to encourage people to study the recognition, diagnosis and innovative treatment of the disease.^{viii}

Figure 2

Current Medicines In Development



SOURCE: PhRMA, "Medicines in Development for Selected Chronic Diseases," 2010.

End Notes

- ⁱ Lopez, Alan; *Global Burden of Disease and Risk Factors*; World Bank, 2006, pg. 89
- ⁱⁱ World Health Organization; *Preventing Chronic Diseases a Vital Investment*; World Health Organization Cataloguing-in-Publication Data, 2005, pg. 2
- ⁱⁱⁱ World Health Organization; *World Health Cardiovascular Factsheet*; 2010, pg. 6
- ^{iv} International Federation of Pharmaceutical Manufacturers and Associations; *Non-Communicable Disease Health Partnerships and Programs Worldwide*"; Compiled from IFPMA's Developing World Partnership Directory (2010) and Global Health Progress; 2010; pg. 21
- ^v International Federation of Pharmaceutical Manufacturers and Associations; *Non-Communicable Disease Health Partnerships and Programs Worldwide*"; Compiled from IFPMA's Developing World Partnership Directory (2010) and Global Health Progress; 2010; pg. 23
- ^{vi} International Federation of Pharmaceutical Manufacturers and Associations; *Non-Communicable Disease Health Partnerships and Programs Worldwide*"; Compiled from IFPMA's Developing World Partnership Directory (2010) and Global Health Progress; 2010; pg. 9
- ^{vii} International Federation of Pharmaceutical Manufacturers and Associations; *Non-Communicable Disease Health Partnerships and Programs Worldwide*"; Compiled from IFPMA's Developing World Partnership Directory (2010) and Global Health Progress; 2010; pg. 3
- ^{viii} Boehringer Ingelheim; *Boehringer Ingelheim in a Day Report*; July 2004; pg. 7-8